KD-496N

KD-496N is an experimental cell therapy currently in the discovery stage of development by KAEDI Medical (Nanjing KAEDI Biotherapeutics). It is categorized as a CAR-NK/T cell therapy, a modality that utilizes engineered cells possessing characteristics of both Natural Killer (NK) cells and T lymphocytes. These cells are typically modified with a Chimeric Antigen Receptor (CAR) to enhance their ability to recognize and eliminate malignant cells. While the specific molecular targets for KD-496N have not been publicly disclosed, the program is part of a broader pipeline focused on treating advanced solid tumors and hematological malignancies. It is distinguished from the related KD-496 program, which is a fourth-generation CAR-T therapy targeting CLDN18.2 and NKG2DL.

Other names

KD-496N CAR-NK/T cell therapy